NFE2L2 and colitis: With the use of schisandrin B, there was a reduction in all inflammatory cytokines expression that had previously been increased, in addition to greater expression of protein p-AMPK and Nrf2, with a reduction in oxidative mitochondrial damage and a relative improvement in colitis.